Alto Neuroscience (ANRO) Equity Ratio (2023 - 2026)

Alto Neuroscience has disclosed Equity Ratio across 4 years of filings, most recently posting 0.88 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.88, up 8.88% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.88 (up 8.88% YoY), and the FY2025 annual result was 0.82, down 4.07% from the prior year.
• Equity Ratio came in at 0.88 for Q1 2026 at Alto Neuroscience, up from 0.82 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.92 in Q1 2024 to a low of 0.83 in Q4 2023.
• The 4-year median for Equity Ratio is 0.84 (2024), against an average of 0.68.
• Across the five-year window, Equity Ratio jumped 203.11% in 2024 and retreated 14.18% in 2025, its largest moves.
• Alto Neuroscience's Equity Ratio stood at 0.83 in 2023, then jumped by 203.11% to 0.85 in 2024, then declined by 4.07% to 0.82 in 2025, then increased by 7.65% to 0.88 in 2026.
• The last three Equity Ratio figures came in at 0.88 (Q1 2026), 0.82 (Q4 2025), and 0.76 (Q3 2025), per Business Quant data.